We conducted a retrospective review of 125 patients undergoing high-dose therapy and stem cell rescue in order to evaluate the incidence of documented infection and the utility of the administration of vancomycin empirically. All patients received prophylactic oral quinolone therapy. Because neutropenia in this setting is relatively brief, 21 patients never manifested fever, and no patient died of infection. Of the remaining 104 patients, positive blood cultures were obtained in only 10, nine with a gram stain positive and one with a gram stain negative organism. Sixty-two patients without any evidence of gram positive infection received vancomycin according to the existing algorithm for care of neutropenic fevers. In this population of patients, empiric administration of vancomycin for neutropenic fevers without culture documentation appears to be unnecessary, could be discontinued safely and at substantial cost savings, and might slow the appearance of vancomycinresistant organisms. Keywords: autologous stem cell transplant; vancomycin; neutropenic fever; infections Infection is a major cause of morbidity and mortality in cancer patients receiving chemotherapy, especially in those undergoing high-dose chemotherapy and bone marrow transplantation. Increased infections in an immunocompromized host are related to neutropenia caused by malignancy and chemotherapeutic agents, the duration of neutropenia, altered immune status, impaired phagocytic function, changes in microbial flora, and the presence of indwelling central venous catheters.
regimens vary, based on considerations of cost, potential for adverse side-effects, prevalent nosocomial infections, and the development of bacterial resistance. The mortality rate from gram negative sepsis in neutropenic patients is 10-30% compared to Ͻ2% from gram positive sepsis. 4 The use of a quinolone antibiotic as prophylaxis has decreased the incidence of gram negative sepsis, 4 whereas the increasing reliance on central lines in intensively treated patients has contributed to an increasing incidence of gram positive infections. 5 Recent data indicate that as many as 75% of bacteremic episodes among febrile neutropenic patients are due to gram positive bacteria. 6 Coagulase negative Staphylococcus, Staphylococcus aureus, Streptococci, Enterococci, and Corynebacteria are the organisms commonly involved.
Given the high mortality of gram negative sepsis in febrile neutropenic patients, immediate institution of empiric antibiotic coverage for gram negative bacteria is routine in the febrile, neutropenic patient. Either monotherapy or combination therapy using third generation cephalosporins, aminoglycosides and/or antipseudomonal penicillins is generally recommended. 6, 7 In randomized studies, ceftazidime appeared to be as good as combination therapy. 8 The lower mortality from gram positive compared to gram negative sepsis led to hesitancy in initiating vancomycin empirically at the inception of fever, in part because of its expense and the potential for the development of resistant organisms from excessive use. 9 Vancomycin is usually administered when blood cultures demonstrate a gram positive organism or when fever persists in the neutropenic patient despite empiric broad-spectrum coverage. 10 In our center, blood cultures are repeatedly obtained in febrile neutropenic patients, and vancomycin is begun for persistent fever even if cultures are negative. It seemed to us that very few of these blood cultures were positive and that the information obtained from positive cultures rarely led to a change in therapy. We therefore retrospectively analyzed sequentially treated patients at our institution who received high-dose chemotherapy followed by autologous peripheral stem cell rescue in order to evaluate the expense and validity of this approach to care, including a determination of how often a positive culture led to a change in therapy, whether clinical correlates identified patients with positive cultures, and what the outcomes were for our patients.
Patients and methods
The charts of 125 patients sequentially treated (from 1993 to 1996) at the Sylvester Cancer Center/Jackson Memorial Hospital at the University of Miami with high-dose chemotherapy followed by autologous peripheral stem cell rescue were evaluated. Patients undergoing autologous bone marrow transplantation or allogeneic transplantation were excluded from the analysis. The patients were housed in the Deed Club Bone Marrow Transplantation Unit of the Jackson Memorial Hospital, which meets the standards of care and infection control (including HEPA filtered air and positive pressure flow) necessary for both allogeneic and autologous bone marrow transplantation. Preparative highdose chemotherapy regimens varied with different presentations and included high doses of alkylating agents used alone or with total body irradiation (in the non-Hodgkin's lymphoma patients). All patients had either double lumen pheresis catheters, portacaths or Hickman catheters.
Neutropenia was defined as an absolute neutrophil count (ANC) Ͻ500/l. Fever was defined as temperature of Ͼ38°C on two separate occasions in 24 h or a single episode of Ͼ38.3°C. All patients received oral prophylaxis with either ciprofloxacin 750 mg or ofloxacin 400 mg twice daily, acyclovir 400 mg twice daily and nystatin troches five times daily starting on day −3 (3 days prior to stem cell reinfusion). Granulocyte colony-stimulating factor (G-CSF) was given at a dosage of 5-10 g/kg daily intravenously starting on day 0 (the day of peripheral stem cell reinfusion) until the total white blood cell count reached Ͼ10 000/l.
In febrile patients, two sets of blood cultures were drawn, one from the central line and the other from the peripheral line, along with a urine culture. For blood cultures, approximately 10 ml of blood were drawn and placed in each of two tubes containing Tryptic Soy Broth with SPS and analyzed by means of an automated system, Bac-T-Alert (Organon-Technika, Durham, NC, USA). If the patient was febrile and neutropenic, intravenous antibiotics were instituted, consisting of ceftazidime 2 g every 8 h or aztreonam 2 g every 6 h plus piperacillin 3 g every 4 h. If fever persisted with a temperature of Ͼ38.3°C, intravenous vancomycin was begun 3 days later at a dose of 1 g every 12 h daily. Finally, if fever persisted for an additional 2-3 days, the patient received intravenous amphotericin B, 0.5 mg/kg i.v. daily. Repeated blood cultures were drawn every 24 h as long as the temperature was Ͼ37.8°C and chest films were also obtained at intervals depending on the number of febrile days, and symptoms. Once intravenous antibiotics were started, oral ciprofloxacin or ofloxacin was discontinued. Some of these patients, however, received vancomycin even while they were afebrile if central line infection was suspected clinically (eg purulent, inflamed appearance of exit site wound). Amphotericin B therapy was instituted sooner for febrile neutropenic patients who had a prior history of fungal infection. Serum vancomycin levels were monitored to maintain peak levels at 20-40 g/ml and trough levels at 5-10 g/ml.
The association of culture positivity with antibiotic use was evaluated with Fisher's exact test. Continuous variables were summarized by median and ranges because most were not normally distributed. In keeping with this, comparisons of continuous outcomes were made with nonparametric Wilcoxon rank sum and Kruskall-Wallis tests as appropriate. In this retrospective analysis, P values р 0.05 were considered to be significant. Table 1 lists the demographics and clinical characteristics of the 125 cases studied. The most frequent diagnoses were breast cancer (53%), non-Hodgkin's lymphoma (23%) and Hodgkin's disease (12%). Three groups of patients were segregated for comparison. No blood cultures were drawn in 21 of the 125 patients because they did not develop fever as defined above. Among the remaining 104 patients who had blood cultures drawn, 94 (90%) had negative blood cultures and 10 (10%) had positive blood cultures. The three categories of patients in Table 1 did not differ significantly based on age, diagnosis, antibiotic prophylaxis or gender. Among the blood culture positive patients, four had breast cancer, two had non-Hodgkin's lymphoma, and one each had Hodgkin's disease, acute myeloid leukemia, acute lymphocytic leukemia and ovarian cancer. Of the 10 positive blood cultures, nine were gram positive organisms and one was gram negative ( Table 2 ). The gram positive bac- ). In six of 10 positive blood cultures, the first blood culture drawn was positive, the second culture was positive in one patient, and it was not until the fifth blood culture that a positive result was obtained in three patients. By the time positive cultures were reported, four patients did not need vancomycin, because the isolated bacteria were sensitive to other antibiotics which patients were receiving per protocol or they had already became afebrile. The only change in ongoing antibiotic administration occurred in the one patient with Alcaligenes xylosooxidans infection. Of the total of 125 patients, three in the febrile culture negative group died of high-dose regimen-related organ toxicity; these three patients had no evidence of infections clinically or microbiologically. No antibiotic-induced renal or hepatic toxicity occurred.
Results
A number of variables potentially associated with blood culture results were evaluated among the patient groups ( Table 3 ). The febrile culture positive groups, compared to the culture positive group, spent more days with an ANC Ͻ500/l (P = 0.0019) and therefore secondarily more days in hospital (P = 0.0004), and demonstrated a trend to a higher frequency of amphotericin administration (P = 0.08).
Cost analysis
Among the 104 febrile patients, a median of three blood cultures were obtained per patient, totaling 280 blood cultures from culture-negative and 36 from culture-positive patients (Table 3 ). The total charges for blood cultures in these patients was $34 128 ($108/culture). Eighty-five patients received vancomycin for a total of 571 days. Among these 85 patients, 18 patients had clinical evidence of catheter-related infection and five had positive blood cultures needing vancomycin. The remaining 62 patients received vancomycin following the Unit's antibiotic guide- Table 3 Clinical variables vs blood culture results a Time of onset of severe neutropenia is indicated in relationship to day 0 (the day of peripheral stem cell reinfusion). LOS = length of stay; ANC = absolute neutrophil count.
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lines for persistent fever, despite the absence of clinical or microbiologic evidence of infection. In our hospital, the charge for each day of vancomycin is $162, and for determining vancomycin peak and trough levels $128 ($64 + $64). The 62 patients treated empirically with vancomycin received a total of 306 days of this antibiotic, resulting in charges of $49 572 for vancomycin and $7936 for determination of peak and trough levels, totaling $57 508.
Discussion
These patients, who received high-dose chemotherapy and peripheral blood stem cell transplantation, were treated initially with oral antibiotic prophylaxis; this was changed to empiric intravenous broad-spectrum antibiotics when febrile neutropenia occurred, in accordance with bone marrow transplant unit guidelines. Prophylactic antibiotics, by reducing the number of febrile days, also reduced the algorithm-driven administration of amphotericin in these patients. 11 The documented bacteremia rate was low (10%), probably also reflecting the use of quinolone prophylaxis and the relatively brief time (median 7 days) that the patients had severe neutropenia. The risk of culture documented bacteremia was highest in our patients who had prolonged neutropenia (Ͼ10 days) as has been noted previously. 1 Prolonged neutropenia was associated with an increased number of febrile days, necessitating an increased frequency of amphotericin B administration in culture positive patients rather than in culture negative patients (40 vs 16%, P = 0.08).
These data raise the question of whether to continue to include vancomycin as part of the protocol of empiric antibiotic therapy or to wait until clinical or microbiologic evidence of infection is obtained. In the current study, 85 patients received vancomycin, including the 18 patients who were treated because of central line-related infection and five patients for positive blood cultures. For the 62 patients who exhibited no objective evidence of gram positive infection, a strong possibility exists that adding vancomycin empirically for continuing fever was unnecessary. Contrariwise, one could argue that a high percentage of febrile neutropenic patients lacked documented gram positive infection precisely because of the empiric administration of vancomycin. In this view, many patients with persistent fever not empirically treated would have subsequently required vancomycin anyway. This is an unlikely event, however, in this particular group of febrile neutropenic patients, because the great majority have rapid blood count recovery after peripheral stem cell infusion, virtually eliminating the risk of prolonged neutropenia. For example, four of the nine patients who had gram positive cultures required no change in antibiotics (no addition of vancomycin) because fever had resolved on the initial broad-spectrum coverage. Moreover, the other five patients where vancomycin was not administered until after positive cultures were obtained experienced no morbidity and mortality because of the delay.
Karp et al 9 in a randomized, double blind study comparing gentamycin and ticarcillin with or without vancomycin found more rapid resolution of fever, fewer febrile days and less frequent use of amphotericin B in the group receiving empiric vancomycin than in the placebo group. In febrile neutropenic patients Rubin et al 12 found gram positive bacteremia in 14% (75 of 550) of febrile episodes and vancomycin was added only after gram positive cultures were obtained rather than empirically, and no excess mortality was reported. They therefore recommended against vancomycin prophylaxis. In a randomized double-blind study, Shenep et al 13 compared vancomycin, ticarcillin and amikacin with ticarcillin-clavulinate and amikacin in febrile neutropenic patients. The vancomycin-treated group experienced a higher incidence of defervescence and decreased bacteremias (treatment success 85 vs 62%), whereas nine breakthrough bacteremias occurred in the group not receiving vancomycin prophylaxis, including one fatal event necessitating the termination of study. The EORTC and NCI of Canada randomized patients to receive ceftazidime and amikacin ± vancomycin and found no increase in the number of febrile days or breakthrough bacteremia in the non-vancomycin-treated group. 14 Ramphal et al 6 in a randomized study concluded that vancomycin can be added after 4 days of monotherapy in persistent febrile neutropenic patients when they compared ceftazidime with or without vancomycin.
Empiric vancomycin therapy added charges of almost $1000 per patient for the 62 patients who lacked documentation of gram positive infection. We believe that performance of blood cultures and withholding of vancomycin unless gram positive cultures are obtained is a costeffective strategy in those patients treated with high-dose chemotherapy and peripheral stem cell rescue who develop febrile neutropenia. This is an important consideration both for patient comfort and to decrease costs as, increasingly, autologous peripheral stem cell transplantation is performed in an outpatient setting. Aside from the economic considerations, decreased utilization of empiric vancomycin would be helpful in slowing the emergence of vancomycin-resistant organisms, a problem of increasing importance. These conclusions apply only to the patients we studied and are not applicable to patients experiencing prolonged neutropenia in other settings, such as intensive conventional chemotherapy for lymphomas and leukemias. Prompt empiric administration of vancomycin is still warranted in the situations of a septic patient whose clinical status is unstable, a high index of suspicion of a gram positive infection (eg inflammation at a catheter exit site wound), or hospital-specific nosocomial data on the prevalence and type of gram positive infections.
